Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing

Abstract

Purpose

Analysis of circulating tumor DNA (ctDNA) offers an unbiased and noninvasive way to assess the genetic profiles of tumors. This study aimed to analyze mutations in ctDNA and their correlation with tissue mutations in patients with a variety of cancers.

Methods

We included 21 cancer patients treated with surgical resection for whom we collected paired tissue and plasma samples. Next-generation sequencing (NGS) of all exons was performed in a targeted human comprehensive cancer panel consisting of 275 genes.

Results

Six patients had at least one mutation that was concordant between tissue and ctDNA sequencing. Among all mutations (n = 35) detected by tissue and blood sequencing, 20% (n = 7) were concordant at the gene level. Tissue and ctDNA sequencing identified driver mutations in 66.67% and 47.62% of the tested samples, respectively. Tissue and ctDNA NGS detected actionable alterations in 57.14% and 33.33% of patients, respectively. When somatic alterations identified by each test were combined, the total proportion of patients with actionable mutations increased to 71.43%. Moreover, variants of unknown significance that were judged likely pathogenic had a higher percentage in ctDNA exclusively. Across six representative genes (PIK3CA, CTNNB1, AKT1, KRAS, TP53, and MET), the sensitivity and specificity of detection using mutations in tissue sample as a reference were 25 and 96.74%, respectively.

Conclusions

This study indicates that tissue NGS and ctDNA NGS are complementary rather than exclusive approaches; these data support the idea that ctDNA is a promising tool to interrogate cancer genetics.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Adzhubei IA et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248–249. https://doi.org/10.1038/nmeth0410-248

  2. Alix-Panabieres C, Pantel K (2014) Challenges in circulating tumour cell research. Nat Rev Cancer 14:623–631. https://doi.org/10.1038/nrc3820

  3. Alix-Panabieres C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as Liquid. Biopsy Cancer Discov 6:479–491. https://doi.org/10.1158/2159-8290.CD-15-1483

  4. Brugger W et al (2011) Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113–4120. https://doi.org/10.1200/JCO.2010.31.8162

  5. Chae YK et al (2017) Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer molecular. Cancer Ther 16:1412–1420. https://doi.org/10.1158/1535-7163.MCT-17-0061

  6. Di Meo A, Bartlett J, Cheng Y, Pasic MD, Yousef GM (2017) Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer 16:80. https://doi.org/10.1186/s12943-017-0644-5

  7. Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579–586. https://doi.org/10.1200/JCO.2012.45.2011

  8. FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer [news release]. Silver Spring, MD: U.S. Food and Drug Administration (2016) https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504488.htm

  9. Kuderer NM, Burton KA, Blau S, Rose AL, Parker S, Lyman GH, Blau CA (2017) Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol 3:996–998. https://doi.org/10.1001/jamaoncol.2016.4983

  10. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protocols 4:1073–1081. https://doi.org/10.1038/nprot.2009.86

  11. Labgaa I, Villacorta-Martin C, D’Avola D, Craig AJ, von Felden J (2018) A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene. https://doi.org/10.1038/s41388-018-0206-3

  12. Mirzaei H, Sahebkar A, Jaafari MR, Goodarzi M, Mirzaei HR (2017) Diagnostic and therapeutic potential of exosomes in cancer: the beginning of a new tale? J Cell Physiol 232:3251–3260. https://doi.org/10.1002/jcp.25739

  13. Mohseni M, Park BH (2010) PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001. J Clin Investig 120:2655–2658. https://doi.org/10.1172/JCI44026

  14. Salvi S, Gurioli G, De Giorgi U, Conteduca V, Tedaldi G, Calistri D, Casadio V (2016) Cell-free DNA as a diagnostic marker for cancer: current insights. OncoTargets Ther 9:6549–6559. https://doi.org/10.2147/OTT.S100901

  15. Schwaederle M et al (2016a) Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell. DNA Assay Oncotarget 7:9707–9717. https://doi.org/10.18632/oncotarget.7110

  16. Schwaederle M et al (2016b) Use of liquid biopsies in clinical oncology: pilot experience in 168 patients. Clin Cancer Res 22:5497–5505. https://doi.org/10.1158/1078-0432.CCR-16-0318

  17. Shihab HA et al (2013) Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden. Markov Models Hum Mut 34:57–65. https://doi.org/10.1002/humu.22225

  18. Siravegna G, Bardelli A (2014) Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol 15:449. https://doi.org/10.1186/s13059-014-0449-4

  19. Siravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14:531–548. https://doi.org/10.1038/nrclinonc.2017.14

  20. Toor OM et al (2018) Correlation of somatic genomic alterations between tissue genomics and ctDNA employing next-generation sequencing: analysis of lung and gastrointestinal cancers. Mol Cancer Ther 17:1123–1132. https://doi.org/10.1158/1535-7163.mct-17-1015

  21. Tseng CP, Leong KK, Liou MJ, Hsu HL, Lin HC, Chen YA, Lin JD (2017) Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary. Thyroid Carcinoma Oncotarget 8:77453–77464. https://doi.org/10.18632/oncotarget.20512

  22. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38:e164. https://doi.org/10.1093/nar/gkq603

  23. Wyatt AW et al (2017) Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx118

  24. Xu CNRM, Wu Z, DiCarlo J, Wang Y (2017) Detecting very low allele fraction variants using targeted DNA sequencing and a novel molecular barcode-aware variant caller. BMC Genom 18:5. https://doi.org/10.1186/s12864-016-3425-4

  25. Yang N et al (2018) The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues. BMC Cancer 18:319. https://doi.org/10.1186/s12885-018-4199-7

  26. Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W (2015) Exosomes in cancer: small particle. Big Player J Hematol Oncol 8:83. https://doi.org/10.1186/s13045-015-0181-x

Download references

Funding

This work has been supported in part by China Medical University Hospital grant (DMR107-100) and Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW107-TDU-B-212-123004).

Author information

Correspondence to Ya-Sian Chang.

Ethics declarations

Conflict of interest

All authors declare that they have no conflicts of interest.

Ethical approval

This study was approved by the Institutional Review Board at the China Medical University Hospital (CMUH106-REC1-047).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chang, Y., Fang, H., Hung, Y. et al. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing. J Cancer Res Clin Oncol 144, 2167–2175 (2018). https://doi.org/10.1007/s00432-018-2747-9

Download citation

Keywords

  • CtDNA
  • NGS
  • Driver mutations
  • Actionable mutations